publication venue for
- Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis.. 28. 2021
- Proteomic analysis shows that the main constituent of subepidermal localised cutaneous amyloidosis is not galectin-7.. 28. 2020
- Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration.. 21. 2014
- Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis.. 18 Suppl 1. 2011
- From hexamer to amyloid: marginal stability of apolipoprotein SAA2.2 leads to in vitro fibril formation at physiological temperature.. 12. 2005
- Suboptimal response for AL amyloidosis: is it time for early switch? Experience from a single amyloid program.. 29. 2022
- Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy).. 22. 2015
- A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred.. 22. 2014
- Systemic transthyretin amyloidosis in a patient with bent spine syndrome.. 20. 2013
- The blue man: a novel cutaneous manifestation of systemic amyloidosis.. 18. 2011
- The 8th International Conference on Alzheimer's Disease and Related Disorders, July 20-25, 2002, Stockholm, Sweden. 2003